MedPath

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Phase 2
Terminated
Conditions
Lymphoma, Non-Hodgkin
Lymphoma, Large B-Cell, Diffuse
Interventions
Registration Number
NCT00529503
Lead Sponsor
Seagen Inc.
Brief Summary

This is a randomized trial to estimate the activity of R-ICE plus SGN-40 vs. R-ICE plus placebo in patients with DLBCL. The study will assess safety and tolerability and will measure any additional clinical benefit observed in patients receiving SGN-40.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
151
Inclusion Criteria
  • Confirmed diagnosis of de novo or transformed DLBCL, or follicular grade 3b lymphoma.
  • Received at least four cycles of first-line therapy with R-CHOP, or equivalent.
  • Best clinical response to first-line therapy of stable disease, partial response, or complete response.
  • At least one measureable lesion that is both greater than or equal to 1.5cm by radiographic imaging and by positive FDG-PET scan.
Exclusion Criteria
  • Leptomeningeal or central nervous system lymphoma.
  • Received any therapy for relapsed or progressive disease except for local radiation, steroids, or rituximab.
  • Received a hematopoietic stem cell transplant.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
2carboplatinplacebo, rituximab, etoposide, carboplatin, ifosfamide
2ifosfamideplacebo, rituximab, etoposide, carboplatin, ifosfamide
1SGN-40SGN-40, rituximab, etoposide, carboplatin, ifosfamide
2placeboplacebo, rituximab, etoposide, carboplatin, ifosfamide
1rituximabSGN-40, rituximab, etoposide, carboplatin, ifosfamide
1carboplatinSGN-40, rituximab, etoposide, carboplatin, ifosfamide
1etoposideSGN-40, rituximab, etoposide, carboplatin, ifosfamide
1ifosfamideSGN-40, rituximab, etoposide, carboplatin, ifosfamide
2rituximabplacebo, rituximab, etoposide, carboplatin, ifosfamide
2etoposideplacebo, rituximab, etoposide, carboplatin, ifosfamide
Primary Outcome Measures
NameTimeMethod
Complete response as assessed by CT and PET scans and revised response criteria for malignant lymphoma.9 weeks
Secondary Outcome Measures
NameTimeMethod
Adverse events, laboratory values, and anti-drug antibody immune responses.9 weeks
Partial response, failure free survival, overall survival, and response for one and two years following treatment.Every 3 months for 2 years

Trial Locations

Locations (66)

Sparrow Regional Cancer Center

🇺🇸

Lansing, Michigan, United States

Washington University School of Medicine

🇺🇸

St. Louis, Missouri, United States

St. Vincent's Hospital, Melbourne

🇦🇺

Fitzroy, Victoria, Australia

The Royal Brisbane and Women's Hospital

🇦🇺

Herston, Queensland, Australia

Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi

🇵🇱

Lodz, Poland

Centrum Onkologii Institut im. Marii Sklodowskiej-Curie

🇵🇱

Warszawa, Poland

Instytut Hematologii i Transfuzjologii

🇵🇱

Warszawa, Poland

University of California at Los Angeles

🇺🇸

Los Angeles, California, United States

Stanford University Medical Center

🇺🇸

Stanford, California, United States

Christiana Care Health Systems

🇺🇸

Newark, Delaware, United States

Georgetown University

🇺🇸

Washington, District of Columbia, United States

Winship Cancer Institute, Emory University

🇺🇸

Atlanta, Georgia, United States

San Juan Oncology Associates

🇺🇸

Farmington, New Mexico, United States

Park Nicollet Institute

🇺🇸

St. Louis Park, Minnesota, United States

Azienda Ospedaliera Universitaria Careggi

🇮🇹

Florence, Italy

Northwestern University

🇺🇸

Chicago, Illinois, United States

Hopitaux du Haut Leveque

🇫🇷

Pessac, France

Institut Gustave-Roussy

🇫🇷

Villejuif, France

Vseobecna fakultni nemocnice v Praze

🇨🇿

Praha 2, Czech Republic

Centre Hospitalier Andre Mignot

🇫🇷

Le Chesnay, France

Centre Henri Becquerel

🇫🇷

Rouen, France

Universitatsklinikum Ulm

🇩🇪

Ulm, Germany

MultiCare Health System

🇺🇸

Tacoma, Washington, United States

Groupe Hospitalier Necker - Enfants Malades

🇫🇷

Paris, France

Royal North Shore Hospital

🇦🇺

St. Leonards, New South Wales, Australia

Ohio State University

🇺🇸

Columbus, Ohio, United States

Baylor Sammons Cancer Center

🇺🇸

Dallas, Texas, United States

St. Vincent's Hospital - Sydney

🇦🇺

Darlinghurst, New South Wales, Australia

AZ Sint-Augustinus

🇧🇪

Wilrijk, Belgium

Royal Perth Hospital

🇦🇺

Perth, Western Australia, Australia

Hopital Hotel Dieu

🇫🇷

Nantes, France

St. Luke's Roosevelt Hospital Center

🇺🇸

New York, New York, United States

Universite de Gent

🇧🇪

Gent, Belgium

Cliniques Universitaires UCL de Mont-Goddine

🇧🇪

Yvoir, Belgium

West Virginia University

🇺🇸

Morgantown, West Virginia, United States

Gosford & Wyong Hospital

🇦🇺

Gosford, New South Wales, Australia

Fakultni nemocnice Hradec Kralove

🇨🇿

Hradec Kralove, Czech Republic

Fakultni nemocnice v Motole

🇨🇿

Praha 5, Czech Republic

Centre Hospitalier Lyon Sud

🇫🇷

Pierre Benite, France

Johannes-Gutenberg Universitat Mainz

🇩🇪

Mainz, Germany

KH Maria Hilf-Franziskushaus

🇩🇪

Monchengladbach, Germany

Centre Leon Berard - Centre regional de lutte contre le cancer Rhone-Alpes

🇫🇷

Lyon, France

Hematologie CHU Purpan

🇫🇷

Toulouse, France

Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikat Kozpont

🇭🇺

Szeged, Hungary

Debreceni Egyetem Orvos - es Egeszsegtudomanyi Centrum

🇭🇺

Debrecen, Hungary

Petz Aladar Megyei Oktato Korhaz, IInd Department of Internal Medicine

🇭🇺

Gyor, Hungary

Kaposi Mor Oktato Korhaz

🇭🇺

Kaposvar, Hungary

Azienda Ospedaliera Universitaria San Martino

🇮🇹

Genova, Italy

Azienda Ospedaliera Universitaria Senese

🇮🇹

Siena, Italy

Szpital Akademii Medycznej w Gdansku

🇵🇱

Gdansk, Poland

Szpital Uniwersytecki w Krakowie

🇵🇱

Krakow, Poland

Hospital Clinic i Provincial

🇪🇸

Barcelona, Spain

Samodzielny Publiczny Szpital Kliniczny Nr 1

🇵🇱

Wroclaw, Poland

Hospital Ramon y Cajal

🇪🇸

Madrid, Spain

Hospital de la Santa Creu i Sant Paul

🇪🇸

Barcelona, Spain

H. Duran y Reynals Institue Catala D'Oncologia

🇪🇸

Barcelona, Spain

Hospital Universitario La Fe

🇪🇸

Valencia, Spain

Cleveland Clinic Foundation

🇺🇸

Cleveland, Ohio, United States

University of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

MD Anderson Cancer Center, Orlando

🇺🇸

Orlando, Florida, United States

University of Louisville - James Graham Brown Cancer Center

🇺🇸

Louisville, Kentucky, United States

Mayo Clinic Rochester

🇺🇸

Rochester, Minnesota, United States

Providence Portland Medical Center

🇺🇸

Portland, Oregon, United States

Medical University of South Carolina

🇺🇸

Charleston, South Carolina, United States

Sarah Cannon Research Institute

🇺🇸

Nashville, Tennessee, United States

University of Texas MD Anderson Cancer Center

🇺🇸

Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath